Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.71 USD
+0.09 (5.56%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.67 -0.04 (-2.34%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Regulus Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 10 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 10 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 31 | 28 | 28 | 24 | 24 |
Income After Depreciation & Amortization | -31 | -28 | -28 | -14 | -17 |
Non-Operating Income | 2 | 1 | 1 | 0 | 0 |
Interest Expense | 1 | 1 | 1 | 2 | 2 |
Pretax Income | -30 | -28 | -28 | -16 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -28 | -28 | -16 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -28 | -28 | -16 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -28 | -27 | -14 | -16 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -31 | -28 | -28 | -14 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.96 | 15.26 | 8.57 | 3.50 | 1.73 |
Diluted EPS Before Non-Recurring Items | -1.58 | -1.86 | -3.20 | -4.50 | -10.80 |
Diluted Net EPS (GAAP) | -1.58 | -1.86 | -3.20 | -4.50 | -10.80 |
Fiscal Year end for Regulus Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 12.26 | 8.83 | 8.30 | 8.13 | 7.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | -12.26 | -8.83 | -8.30 | -8.13 | -7.32 |
Non-Operating Income | 1.28 | 0.44 | 0.35 | 0.44 | 0.47 |
Interest Expense | 0.06 | 0.08 | 0.11 | 0.14 | 0.17 |
Pretax Income | -11.04 | -8.47 | -8.06 | -7.82 | -7.01 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -11.04 | -8.47 | -8.06 | -7.82 | -7.01 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -11.04 | -8.47 | -8.06 | -7.82 | -7.01 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 64.47 | 28.75 | 20.22 | 19.63 | 19.10 |
Diluted EPS Before Non-Recurring Items | -0.17 | -0.29 | -0.40 | -0.40 | -0.37 |
Diluted Net EPS (GAAP) | -0.17 | -0.29 | -0.39 | -0.40 | -0.37 |